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Abstract Trichosanthin (TCS) is a type I ribosome-inactivating
protein that has a wide range of pharmacological activities. The
present study investigated the effectiveness of TCS on herpes
simplex virus (HSV-1). The anti-viral activity and toxicity of
TCS on Vero cells were measured. Results showed that the ED50,
TD50 and the therapeutic indices were 38.5, 416.5 and 10.9 Wg/
ml, respectively. Anti-viral activity of TCS was substantially
potentiated when it was used in conjunction with other anti-viral
agents. The ED50 of TCS was reduced 125-fold by acyclovir at a
concentration of 0.001 Wg/ml, which was practically devoid of
significant anti-viral activity. Similarly, the ED50 of TCS was
reduced 100-fold by interferon-K2a at a concentration of 100 IU/
ml. In conclusion, TCS is effective against HSV-1 and other anti-
viral agents such as acyclovir or interferon can potentiate its
action substantially. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Trichosanthin (TCS) is a type I ribosome-inactivating pro-
tein (RIP) puri¢ed from the root tubers of Trichosanthes kiri-
lowii [1]. In the crude form, it was used in ancient China as an
abortifacient agent. After TCS was puri¢ed and identi¢ed to
be the active ingredient, more biological activities of this com-
pound were unveiled [2]. A major ¢nding was that TCS in-
hibited the replication of human immunode¢ciency virus
(HIV) in both acutely infected T-lymphoblastoid cells and
chronically infected macrophage [3]. This generated great en-
thusiasm leading to phase I/II clinical trials. It was shown that
TCS lowered serum p24 antigen level and increased CD4 T
cells in HIV-infected patients [4,5]. However, antigenicity and
other side e¡ects precluded further investigation of its poten-
tial use as a therapeutic agent. There have been e¡orts to
reduce the antigenicity of TCS by molecular manipulation
and coupling to PEG [6].
Type 1 (HSV-1) and type 2 (HSV-2) herpes simplex virus
are responsible for a broad spectrum of human infectious
diseases. They range in severity from herpes labialis, genital
herpes, herpes keratitis, to the life-threatening herpes encepha-
litis [7]. HSV infections were also recognized as a risk factor
for HIV infection and can be lethal to AIDS patients [8].
There is only a limited choice of drugs currently available
for the management of HSV infection. The list includes inter-
ferons (INFs), acyclovir (ACV), vidarabine, ganciclovir and
foscarnet. All these drugs have undesirable complications and
may induce resistance [7]. It is therefore necessary to expand
the scope of anti-HSV agents. Combination of di¡erent anti-
viral drugs working via di¡erent mechanisms proved to be
e¡ective. It appears that TCS, being an RIP, has a unique
mechanism compared to the conventional ones. It can play
an attractive role in combination therapy. In this study, the
e¡ect of TCS on HSV-1 was investigated. The potentiation
e¡ect when used in conjunction with other anti-viral drugs
was also explored.
2. Materials and methods
2.1. Reagents
TCS was obtained from Professor Y.B. Ke of the Shanghai Insti-
tute of Cell Biology, the Chinese Academy of Sciences. Recombinant
human INF-K2a was generously provided by Changsheng Gene
Pharm Co. Ltd. (China).
2.2. Cells and virus
Vero cell (African green monkey kidney cell, ATCC CCL 81) and
HSV-1 (F strain, ATCC VR733) were obtained from the American
Type Culture Collection (Rockville, MD, USA). Vero cells were main-
tained in culture £asks in complete RPMI medium. Subculture was
done every 2^3 days after it had formed a con£uent monolayer. Dur-
ing subculture, cells that attached to the culture £asks were trypsi-
nized (0.25% trypsin containing 0.01% EDTA) for 2^5 min at 37‡C
and then stopped by the addition of complete medium to the cell
suspension. The cells were washed once again with complete medium.
About 105 viable cells were then re-suspended in complete medium.
HSV-1 was propagated in Vero cells and the viral titers were deter-
mined by plaque formation. The infectious titer of stock solution was
106 TCID50/ml (50% tissue culture infectious doses).
2.3. Cytotoxicity assay
Cytotoxicity was measured by the XTT method using the Cell Pro-
liferation Kit II (Boehringer-Mannheim). Brie£y, 100 Wl of Vero cells
(1U105/ml) was seeded onto a microtiter plate and allowed to attach
to the well bottom. Various concentrations of anti-viral agents were
added and incubated for 48 h. XTT reagent was added to a ¢nal
concentration of 0.3 mg/ml. Absorbance of the color complex was
read at 490 nm with the reference wavelength set at 690 nm. TD50
was de¢ned as the concentration of the anti-viral agent at which ab-
sorbance was reduced by 50%.
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2.4. Anti-herpetic activity assay
Vero cells (1U104 cells/well) were seeded onto the microtiter plate
and allowed to attach to the well bottom. The cells were pre-incubated
with a single or combination of the anti-viral agents for 2 h. HSV-1
containing 10 TCID50 per well was added and incubated for 48 h [9].
Replication of HSV-1 was determined by in situ HSV antigen ELISA
assay using peroxidase-conjugated rabbit anti-HSV-1 antibody
[10,11]. The concentration of an anti-viral agent reducing HSV-1
replication by 50% (ED50) was determined from the dose^response
curve. The therapeutic index (TI) was calculated from the ratio of
TD50/ED50.
3. Results
3.1. Cytotoxicity and anti-herpetic activity of TCS, ACV and
INF
TCS, ACV and INF exhibited a dose-dependent inhibitory
e¡ect on HSV-1 replication (Figs. 1 and 2). The ED50, TD50
and TI are summarized in Table 1. On a molar basis, the
potency of TCS is similar to ACV (ED50 1.4 WM and 1.2
WM, respectively), whereas the toxicity of TCS is much higher.
3.2. ACV and INF enhanced anti-herpetic activity of TCS
The anti-viral e¡ects of TCS used in conjunction with ACV
or INF are summarized in Figs. 3 and 4. Both demonstrate
that it was substantially potentiated. ACV at a concentration
of 0.001 Wg/ml was practically inactive (Figs. 2A and 3A). The
ED50 of TCS determined in the presence of this amount of
ACV was signi¢cantly decreased by 125-fold from 64.7 þ 16.2
to 0.52 þ 0.18 Wg/ml (Fig. 4A). A similar ¢nding was observed
when TCS was used in conjunction with INF. The ED50 was
reduced by 100-fold from 64.7 þ 16.2 to 0.62 þ 0.06 Wg/ml (Fig.
4B). The concentration of INF used together with TCS (100
IU/ml) contained minimal anti-viral activity (Figs. 2B and
3B).
4. Discussion
It was found that TCS inhibited replication of HIV, but its
action on other viruses is not known. The present investiga-
tion examines the e⁄cacy of TCS on HSV as well as its com-
bined e¡ect with other anti-viral agents. It was clearly dem-
onstrated that TCS is active against HSV and its e⁄cacy is
similar to ACV on a molar basis. TCS is more toxic than
ACV and therefore the calculated TI is smaller. Toxicity of
TCS varies between cell types, for example, choriocarcinoma
is much more sensitive to TCS than hepatoma [6]. Vero cells
were used as hosts in this study and this cell line is not par-
ticularly sensitive to TCS.
Combination therapy using more than one anti-viral agent
has been demonstrated to be e¡ective against some viral dis-
eases [12,13]. In this study, the synergistic e¡ect of TCS with
two other anti-viral agents was investigated. The ¢rst is ACV,
which is commonly used for treatment of HSV infection. It
targets viral DNA polymerase after being phosphorylated by
HSV-speci¢c thymidine kinase [7]. It is therefore active only in
Fig. 1. Anti-herpetic activity and cytotoxicity of TCS. Data are ex-
pressed as means þ S.E.M. of triplicate measurements (n = 7).
Fig. 2. Anti-herpetic activity and cytotoxicity of ACV (A) and INF-
K2a (B). Data are expressed as means þ S.E.M. of triplicate mea-
surements (n = 4).
Table 1
Summary of the cytotoxicity and anti-viral activity of TCS, ACV and INF-K2a
Compound ED50 TD50 TI
TCS 38.4 þ 17.5 Wg/ml 416.5 þ 34.5 Wg/ml 10.8
ACV 0.27 þ 0.02 Wg/ml s 500 Wg/ml s 1850
IFN-K2a 1007 þ 69.5 IU/ml s 5000 IU/ml s 4.9
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infected cells. The other anti-viral agent is INF. Its action
depends on the kind of INF and the type of cells [14]. Vero
cells are not particularly sensitive to INF-K2a used in this
study. The anti-viral mechanism of INF is not well estab-
lished. It is known that treatment of HSV-infected cells re-
sulted in a decrease of ribonucleotide reductase leading to a
fall in the size of deoxyribonucleotide pools [15,16]. In this
study, it was clearly demonstrated that ACV or INF enhanced
the anti-viral action of TCS. In the presence of a ¢xed low
dosage of either ACV or INF that has no signi¢cant anti-viral
e¡ect, the potency of TCS was enhanced by over 100-fold.
How RIP inhibits viral replication is not clear. Intuitively, it
may be attributed to ribosome inactivation. However, not all
RIPs are anti-viral. There is evidence to suggest that the anti-
viral mechanism of some RIPs does not involve ribosome
inactivation [17]. The anti-viral action of pokeweed anti-viral
protein is due to selective inhibition of DNA synthesis [18].
Momordica anti-viral protein 30 and Gelonium anti-viral pro-
tein 31 are believed to inhibit viral integrase activity [19].
Although some biological activities of TCS can be explained
by ribosome inactivation, the exact mechanism of anti-viral
activities remains to be determined. There may not be enough
information from this study to suggest any plausible mecha-
nism for TCS action. But it can be speculated that the anti-
viral mechanism of TCS should not be the same as that of
ACV or INF. Alternatively, if the mechanisms were the same,
the synergistic e¡ect would have been summative rather than
100-fold potentiated as found in this study.
In conclusion, this study shows that TCS is active against
HSV and this action can be potentiated by ACV or INF.
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